Cargando…
Icosapent Ethyl – A Successful Treatment for Symptomatic COVID-19 Infection
COVID-19 is a fatal, universal pandemic caused by the SARS-CoV-2 virus that has directly caused at least 95,235 deaths in the US by May 2020. It has a poor prognosis with a mortality rate as high as 21% in the general population at the height of the pandemic, a rate that is much higher in elderly pa...
Autores principales: | Berger, Amnon A, Sherburne, Robert, Urits, Ivan, Patel, Haresh, Eskander, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532870/ https://www.ncbi.nlm.nih.gov/pubmed/33033686 http://dx.doi.org/10.7759/cureus.10211 |
Ejemplares similares
-
Icosapent Ethyl (Vascepa®) for the Treatment of Acute, Severe Pancreatitis
por: Berger, Amnon A, et al.
Publicado: (2020) -
Three Cases of COVID-19 Pneumonia That Responded to Icosapent Ethyl Supportive Treatment
por: Suh, Winston, et al.
Publicado: (2020) -
Adductor Canal Block Duration of Analgesia Successfully Prolonged With Perineural Dexmedetomidine and Dexamethasone in Addition to IPACK Block for Total Knee Arthroplasty
por: Herman, Jared, et al.
Publicado: (2020) -
Fascia Iliaca Block Successfully Prolonged With Dexmedetomidine and Dexamethasone for Pain Control in a Patient Undergoing Total Hip Arthroplasty
por: Noor, Nazir A, et al.
Publicado: (2020) -
Synergistic Effect of Perineural Dexamethasone and Dexmedetomidine (Dex-Dex) in Extending the Analgesic Duration of Pectoral Type I and II Blocks
por: Zusman, Robert P, et al.
Publicado: (2020)